Incidence of and Risk Factors for Hepatic Encephalopathy in a Population-Based Cohort of Americans With Cirrhosis - PubMed (original) (raw)
. 2019 Sep 6;3(11):1510-1519.
doi: 10.1002/hep4.1425. eCollection 2019 Nov.
Affiliations
- PMID: 31701074
- PMCID: PMC6824059
- DOI: 10.1002/hep4.1425
Incidence of and Risk Factors for Hepatic Encephalopathy in a Population-Based Cohort of Americans With Cirrhosis
Elliot B Tapper et al. Hepatol Commun. 2019.
Abstract
Hepatic encephalopathy (HE) is a devastating complication of cirrhosis. Data are limited regarding the incidence of and risk factors for HE among contemporary patients in the context of the shifting epidemiology of cirrhosis. We examined a 20% random sample of U.S. Medicare enrollees with cirrhosis and Part D prescription coverage from 2008 to 2014. We modelled incident HE using demographic, clinical, and pharmacologic data. Risk factors for HE were evaluated, including demographics/socioeconomics, cirrhosis etiology, severity of liver disease, and pharmacotherapy, along with gastroenterology consultation, as time-varying covariates. Among 166,192 Medicare enrollees with cirrhosis followed for 5.25 (interquartile range [IQR], 2.00-7.00) years, the overall incidence of HE was 11.6 per 100 patient-years. The cohort's median age was 65 years (IQR, 57-72), 31% had alcohol-related cirrhosis, and 49% had likely nonalcoholic fatty liver disease cirrhosis. The two strongest associations with HE were alcohol-related cirrhosis (adjusted hazard ratio [AHR], 1.44; 95% confidence interval [CI], 1.40, 1.47, relative to nonalcoholic nonviral cirrhosis) and the presence of portal hypertension (AHR, 3.42; 95% CI, 3.34, 3.50). Adjusting for confounders, benzodiazepines (AHR, 1.24; 95% CI, 1.21, 1.27), gamma aminobutyric acid (GABA)ergics (AHR, 1.17; 95% CI, 1.14, 1.21), opioids (AHR, 1.24; 95% CI, 1.21, 1.27), and proton pump inhibitors (PPIs) (AHR, 1.41; 95% CI, 1.38, 1.45) were all associated with incident HE. Only benzodiazepines, however, were associated with the risk of hospitalization with HE (incidence-rate ratio, 1.23; 95% CI, 1.20, 1.26). Conclusion: Novel data regarding the risk of HE for contemporary patients with cirrhosis are provided. The incidence of HE in an older population of Americans with cirrhosis is high, particularly among those with alcohol-related cirrhosis and portal hypertension. Several medication classes, namely PPIs, opiates, GABAergics, and benzodiazepines, represent potentially modifiable risk factors for HE.
© 2019 The Authors. Hepatology Communications published by Wiley Periodicals, Inc., on behalf of the American Association for the Study of Liver Diseases.
Similar articles
- Outcomes after hepatic encephalopathy in population-based cohorts of patients with cirrhosis.
Tapper EB, Aberasturi D, Zhao Z, Hsu CY, Parikh ND. Tapper EB, et al. Aliment Pharmacol Ther. 2020 Jun;51(12):1397-1405. doi: 10.1111/apt.15749. Epub 2020 May 3. Aliment Pharmacol Ther. 2020. PMID: 32363684 Free PMC article. - Reduced Incidence of Hepatic Encephalopathy and Higher Odds of Resolution Associated With Eradication of HCV Infection.
Tapper EB, Parikh ND, Green PK, Berry K, Waljee AK, Moon AM, Ioannou GN. Tapper EB, et al. Clin Gastroenterol Hepatol. 2020 May;18(5):1197-1206.e7. doi: 10.1016/j.cgh.2019.09.033. Epub 2019 Oct 4. Clin Gastroenterol Hepatol. 2020. PMID: 31589975 Free PMC article. - Racial and ethnic disparities in rifaximin use and subspecialty referrals for patients with hepatic encephalopathy in the United States.
Tapper EB, Essien UR, Zhao Z, Ufere NN, Parikh ND. Tapper EB, et al. J Hepatol. 2022 Aug;77(2):377-382. doi: 10.1016/j.jhep.2022.02.010. Epub 2022 Mar 30. J Hepatol. 2022. PMID: 35367057 - Incidence of, Risk Factors for, and Outcomes After Ascites in a Population-Based Cohort of Older Americans.
Tapper EB, Zhao Z, Mazumder N, Parikh ND. Tapper EB, et al. Dig Dis Sci. 2022 Nov;67(11):5327-5335. doi: 10.1007/s10620-022-07454-3. Epub 2022 Mar 9. Dig Dis Sci. 2022. PMID: 35262903 Free PMC article. - Overview of Complications in Cirrhosis.
Premkumar M, Anand AC. Premkumar M, et al. J Clin Exp Hepatol. 2022 Jul-Aug;12(4):1150-1174. doi: 10.1016/j.jceh.2022.04.021. Epub 2022 May 14. J Clin Exp Hepatol. 2022. PMID: 35814522 Free PMC article. Review.
Cited by
- The Value of Ammonia as a Biomarker in Patients with Cirrhosis.
Ballester MP, Durmazer EN, Qi T, Jalan R. Ballester MP, et al. Semin Liver Dis. 2024 Aug;44(3):356-368. doi: 10.1055/a-2378-8942. Epub 2024 Aug 2. Semin Liver Dis. 2024. PMID: 39095029 Free PMC article. Review. - Racial and Ethnic Disparities in Outcomes After the Development of Ascites: A National Cohort Study.
Solano QP, Chen X, Parikh ND, Tapper EB. Solano QP, et al. Dig Dis Sci. 2024 Sep;69(9):3214-3219. doi: 10.1007/s10620-024-08572-w. Epub 2024 Jul 30. Dig Dis Sci. 2024. PMID: 39080087 - Medication burden and anticholinergic use are associated with overt HE in individuals with cirrhosis.
Montrose JA, Desai A, Nephew L, Patidar KR, Ghabril MS, Campbell NL, Chalasani N, Qiu Y, Hays ME, Orman ES. Montrose JA, et al. Hepatol Commun. 2024 Jul 22;8(8):e0460. doi: 10.1097/HC9.0000000000000460. eCollection 2024 Aug 1. Hepatol Commun. 2024. PMID: 39037388 Free PMC article. - Opioid use and risks in candidates and recipients of liver transplant.
Rubin JB, Aby ES, Barman P, Tincopa M. Rubin JB, et al. Liver Transpl. 2024 Apr 29:10.1097/LVT.0000000000000388. doi: 10.1097/LVT.0000000000000388. Online ahead of print. Liver Transpl. 2024. PMID: 38669598 - A Prospective Multimodal Education Intervention for Providers Does Not Increase Hepatic Encephalopathy Treatment Rates.
Twohig PA, Peeraphatdit TB, Samson K, Schissel M, Smith L, Ashford A, Freese L, McCashland T. Twohig PA, et al. Dig Dis Sci. 2024 Jun;69(6):1996-2007. doi: 10.1007/s10620-024-08445-2. Epub 2024 Apr 23. Dig Dis Sci. 2024. PMID: 38652390
References
- Bajaj JS, Wade JB, Sanyal AJ. Spectrum of neurocognitive impairment in cirrhosis: implications for the assessment of hepatic encephalopathy. Hepatology 2009;50:2014‐2021. - PubMed
- Tapper EB, Risech‐Neyman Y, Sengupta N. Psychoactive medications increase the risk of falls and fall‐related injuries in hospitalized patients with cirrhosis. Clin Gastroenterol Hepatol 2015;13:1670‐1675. - PubMed
- Ezaz G, Murphy SL, Mellinger J, Tapper EB. Increased morbidity and mortality associated with falls among patients with cirrhosis. Am J Med 2018;131:645‐650.e2. - PubMed
- Beste LA, Leipertz SL, Green PK, Dominitz JA, Ross D, Ioannou GN. Trends in burden of cirrhosis and hepatocellular carcinoma by underlying liver disease in US veterans, 2001‐2013. Gastroenterology 2015;149:1471‐1482.e5. - PubMed
LinkOut - more resources
Full Text Sources